New insights into the unique nature of colorectal cancer peritoneal metastases-rethinking HIPEC

Author(s): Ramsay, RG; Flood, M;
Details: Publication Year 2022-08,Volume 127,Issue #3,Page 377-378
Journal Title: British Journal of Cancer
Publication Type: Editorial
Abstract: Colorectal peritoneal metastases (CRPM) can be resistant to the chemotherapy agent (oxaliplatin) most employed, up until recently, as hyperthermic intraperitoneal chemotherapy (HIPEC). Glutathione-mediated inactivation of oxaliplatin can be substantially reduced by genomic deletion of the gene or pharmacological inhibition of glutamate-cysteine ligase in CRPM tumouroids. These discoveries may rekindle the enthusiasm for HIPEC in concert with cytoreductive surgery, which has been employed to manage patients with this once-nihilistic form of stage-IV disease.
Keywords: Antineoplastic Combined Chemotherapy Protocols/therapeutic use; *Colorectal Neoplasms/drug therapy/pathology; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; *Hyperthermia, Induced; Hyperthermic Intraperitoneal Chemotherapy; Oxaliplatin/therapeutic use; *Peritoneal Neoplasms/drug therapy/pathology; Survival Rate
Department(s): Laboratory Research; Surgical Oncology
PubMed ID: 35831561
Publisher's Version: https://doi.org/10.1038/s41416-022-01905-4
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-03-07 02:36:22

Last Modified: 2025-03-07 02:38:23